Clicky

Creso Pharma Ltd(COPHF)

Description: Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX®nite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.


Keywords: Drugs Cannabis Health Sciences Entheogens Euphoriants Medicinal Plants Hemp Medical Cannabis Herbalism Herbs Skin Care Products Cannabidiol Therapeutic Products Nutraceutical Products Nutraceutical Product Pharmaceutical Grade Cannabis Hemp Based Nutraceutical Products

Home Page: melodiolglobalhealth.com

145 Stirling Highway
Nedlands, WA 6009
Australia
Phone: 61 8 9389 3180


Officers

Name Title
Mr. Boaz Wachtel M.A., M.D., MBA Co-Founder & Non-Executive Chairman
Mr. William Lay B.Com. Group CEO, MD & Director
Mr. Christopher Grundy BCom, FCA, FCIS, GAICD Chief Financial Officer
Ms. Micheline MacKay B.Sc., M.Sc., P.M.P. Executive Director
Dr. Gian Trepp Commercial & Marketing Director
Mr. Mitchel Fleming Managing Director of Halucenex
Brett Ayers Managing Director of Impactive
Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom Joint Company Secretary
Hon. Brian Walker Strategic Consultant & Chair of Scientific Advisory Committee

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.0553
Price-to-Sales TTM: 6.9617
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks